Kohlschütter–Tönz Syndrome (KTS)

Kohlschütter–Tönz syndrome (KTS) is a very rare inherited condition. It usually starts in the first year of life. The key signs are: seizures (epilepsy), slow development or loss of skills, and a tooth-enamel problem called amelogenesis imperfecta that makes teeth thin, weak, and yellow-brown. The condition is usually passed down in an autosomal recessive way, meaning a child gets one non-working copy of the gene from each parent. In most families, the cause is a change (mutation) in a gene called ROGDI. This gene seems important for brain development and for making normal tooth enamel. Because the seizures can be frequent and hard to control, doctors often describe KTS as an epileptic encephalopathy—that is, the epilepsy itself can worsen thinking and movement over time. NCBI+1

Kohlschütter–Tönz syndrome is a very rare inherited condition. It mainly shows three things together: early seizures, slow or lost development of skills, and teeth enamel that is weak, thin, soft, or yellow (a problem called “amelogenesis imperfecta”). Most families have changes (variants) in a gene called ROGDI. Less often, changes in SLC13A5 can cause a similar picture. The condition is passed in an autosomal recessive way, which means a child must inherit the non-working gene from both parents. Doctors often first notice KTS because of the teeth changes, and then confirm it with genetic testing. Brain scans and EEG tests can help show how the brain is affected, but the final diagnosis comes from the gene test. Turkish Archives of Pediatrics+2PMC+2

Some research and summaries also note a small number of families with a very similar pattern caused by changes in SLC13A5 (a citrate transporter gene). Many experts now treat SLC13A5 disease as a separate but overlapping disorder; historically it was sometimes grouped with KTS because the symptoms look alike (seizures plus enamel defects). When you read older articles, you may see the names used together. Newer papers and case series tend to keep ROGDI-related KTS as the classic form. Wikipedia+1

---

Other names

1. Epilepsy–dementia–amelogenesis imperfecta syndrome. This name lists the three main problems: seizures, thinking/behavior decline, and weak enamel. Wikipedia

2. Amelocerebrohypohidrotic syndrome. This older term highlights enamel defects (“amelo-”), brain problems (“cerebro-”), and reports of reduced sweating (“hypohidrotic”) in some cases. It appears in rare-disease catalogs and older papers. Orpha

3. ROGDI-related epileptic encephalopathy with amelogenesis imperfecta. This modern label ties the syndrome to its usual gene cause. PubMed

---

Types

1. Type 1 (Classic, ROGDI-related KTS). This is the best-defined form. It has early-onset seizures, global developmental delay, often spasticity, and enamel defects in both baby and adult teeth. Many different ROGDI variant types have been reported (nonsense, frameshift, splice-site, and deletions), but the clinical picture is similar. PMC+2PubMed+2

2. KTS-like or “overlap” form (SLC13A5-related). Some authors used to include SLC13A5 disease under the KTS umbrella because of similar signs (seizures + enamel defects). Today, many classify SLC13A5 citrate transporter disorder as a separate condition that mimics parts of KTS. This matters for genetic counseling and research, so the gene test helps tell them apart. Wikipedia+1

---

Causes

Important note: the direct cause of KTS is biallelic pathogenic variants (two harmful copies) in the ROGDI gene. The items below explain known mutation types and genetic contexts that can “cause” or strongly increase the chance of KTS. Some are mechanisms (what goes wrong in the gene); others are risk settings (why it happens more in some families). PMC+1

1. Biallelic loss-of-function mutations in ROGDI. Two non-working copies stop the protein from doing its job in brain and enamel development. PMC

2. Nonsense variants in ROGDI. A premature “stop” signal produces a short, useless protein. Several families have this pattern. Wikipedia

3. Frameshift variants in ROGDI. An extra or missing DNA letter shifts the reading frame, creating a broken protein. Wikipedia

4. Splice-site variants in ROGDI. Mistakes at intron–exon boundaries lead to mis-spliced RNA and a faulty protein. Wikipedia

5. Whole-gene or multi-exon deletions. Larger missing segments remove essential parts of the gene. Case reports describe such deletions. jbcgenetics.com

6. Compound heterozygosity. One harmful variant is inherited from each parent, but they are different types (for example, one nonsense + one splice variant). PubMed

7. Homozygous variants due to parental relatedness. When parents are related (consanguinity), the chance of receiving the same rare variant from both parents goes up. PubMed

8. Founder variants in certain populations. Some small or isolated populations can share a recurrent disease-causing change, as reported in specific families. PubMed

9. ROGDI variants that trigger nonsense-mediated decay. The cell destroys the faulty message before a protein can be made, effectively causing a loss of function. Wikipedia

10. Missense variants with major structural impact. Rarely, a single amino-acid change can disrupt protein structure enough to mimic loss of function. PubMed

11. ROGDI regulatory region variants (suspected). Non-coding changes could reduce gene expression; evidence is limited but biologically plausible. (This is an inference from gene biology; confirmatory data are sparse.) PMC

12. Chromosomal microdeletions including ROGDI. Copy-number changes that remove ROGDI alongside neighbors can cause a KTS phenotype. jbcgenetics.com

13. Altered ROGDI interactions (e.g., with DISC1). Lab studies suggest ROGDI may interact with DISC1, a brain-development protein; disruption could contribute to disease. PMC

14. KTS-like disease from SLC13A5 variants. Not classic KTS, but can “cause” a near-identical clinical picture in some older reports. Gene testing separates them. PubMed

15. Autosomal recessive inheritance pattern itself. This mode of inheritance is the root reason both copies must be faulty to show disease. NCBI

16. Low fetal brain expression pattern of ROGDI. Expression studies (low in fetal brain, higher after birth) may explain why symptoms start after the first weeks. This supports causality timing. Wikipedia

17. Loss of enamel-formation signaling. ROGDI is thought to be important in ameloblast function; losing it helps explain enamel defects. (Mechanistic evidence from human genetics and animal models.) PMC+1

18. Neuronal development disturbance. ROGDI disruption likely affects neuronal maturation and network formation, which can drive epileptic encephalopathy. PMC

19. Possible parallels to V-ATPase–related disease. Newer lab work notes overlaps in biology, hinting at broader cellular pathways behind KTS. ScienceDirect

20. Rare reported systemic features (e.g., nephrocalcinosis) in some ROGDI cases. These do not “cause” KTS but reflect the gene’s wider roles and may result from the same underlying defect. Nature

---

Symptoms and signs

1. Seizures beginning in infancy. Often start in the first year. They can be frequent and hard to control. This is the most consistent sign. NCBI

2. Developmental delay. Children reach milestones late (sitting, walking, talking), and may need ongoing therapy. NCBI

3. Loss of skills (regression) in some children. After seizures worsen, a child may lose abilities they had learned. NCBI

4. Amelogenesis imperfecta (AI). Baby and adult teeth have thin, soft enamel that chips and wears down, with a yellow-brown look. Wikipedia

5. Spasticity or stiff muscles. Over time, some children develop increased muscle tone and tightness. NCBI

6. Feeding difficulties and poor weight gain. Coordination and tone issues can make feeding hard. NCBI

7. Speech delay or limited speech. Both the epilepsy and the brain-development issue can affect language. NCBI

8. Behavioral challenges. Irritability, sleep problems, or hyperactivity can occur. Severity varies. NCBI

9. Hypotonia early on. Some babies feel “floppy” first, before spasticity develops. NCBI

10. Ataxia or poor coordination. Balance and fine motor control may be affected. NCBI

11. Microcephaly (small head) in some. Not universal, but reported. Wikipedia

12. Distinct dental sensitivity and pain. Thin enamel makes teeth sensitive to hot/cold and at risk for cavities and wear. Wikipedia

13. Abnormal sweating (reduced) reported in some. This is part of the older “amelocerebrohypohidrotic” name, but not seen in every child. Orpha

14. Characteristic facial or limb traits in a few cases. Examples include up-slanting eye openings, smooth philtrum, broad thumbs or toes; these are not required for diagnosis. Wikipedia

15. Possible kidney calcium deposits (nephrocalcinosis) in rare cases. A newer observation in ROGDI-related KTS. Nature

---

Diagnostic tests

A) Physical examination

1. General pediatric and neurologic exam. The doctor looks for developmental level, muscle tone, reflexes, and signs of spasticity. This helps document the encephalopathy pattern. NCBI

2. Detailed dental exam. A dentist evaluates color, thickness, and strength of enamel in baby and adult teeth to recognize amelogenesis imperfecta typical of KTS. Wikipedia

3. Growth and nutrition assessment. Measuring weight, length/height, and head size helps track nutrition and microcephaly risk. NCBI

4. Skin and sweating check. Some reports describe reduced sweating; the clinician may ask about heat intolerance or dry skin. Orpha

5. Observation of seizure types. Caregivers describe events; the clinician notes features like stiffening, jerking, or staring to guide EEG testing. NCBI

B) Manual / bedside assessments

6. Developmental screening tools (e.g., milestone checklists). Simple, structured checklists map what skills are present or delayed. NCBI

7. Functional feeding evaluation. A speech-language or occupational therapist observes sucking, chewing, and swallowing to plan safe feeding. NCBI

8. Tone and range-of-motion assessment. Physical therapists measure stiffness and flexibility to plan stretching and positioning. NCBI

9. Dental sensitivity testing. Gentle air, cold, or touch helps gauge enamel loss and tooth pain to plan protective treatments. Wikipedia

C) Laboratory and pathological tests

10. Targeted ROGDI gene sequencing. This is the key test to confirm classic KTS. It looks for known and new variants in ROGDI. preventiongenetics.com

11. Deletion/duplication analysis (copy-number testing). If sequencing is negative, a lab can look for missing or extra pieces of the ROGDI gene. jbcgenetics.com

12. Whole-exome or genome sequencing. Broader tests can find rare or unexpected variants and separate KTS from SLC13A5-related conditions. PubMed

13. Chromosomal microarray. This checks for larger deletions/duplications that include ROGDI. It is useful when the clinical picture fits but sequencing is unclear. jbcgenetics.com

14. Basic metabolic workup (to rule out mimics). Blood and urine screens help exclude other causes of infantile seizures and regression, ensuring the diagnosis is correct. NCBI

15. (Research) Enamel histology when needed. Rarely, dentists may study enamel structure to document AI pattern; genetics is preferred for diagnosis today. Wikipedia

D) Electrodiagnostic tests

16. Standard EEG. Records brain waves to confirm epilepsy and classify seizure types. KTS EEGs often show patterns of epileptic encephalopathy. NCBI

17. Prolonged or video-EEG monitoring. Links EEG changes to visible events, helps adjust medicines, and clarifies seizure burden over time. NCBI

18. Evoked potentials (case-by-case). These measure the brain’s response to sound or light and may support global brain involvement when the picture is complex. NCBI

E) Imaging tests

19. Brain MRI. Looks for signs of brain volume loss, white-matter changes, or other structural findings. Results vary; some children have nonspecific changes. NCBI

20. Dental panoramic X-ray (OPG). Shows thin enamel and rapid wear of teeth across the whole mouth, supporting the diagnosis of AI in KTS. Wikipedia

Non-pharmacological treatments (therapies and others)

Each item includes a short description, its purpose, and the likely mechanism in simple words.

1. Seizure first-aid and safety training
   Description: Teach caregivers what to do during a seizure (protect head, time the event, place on side, know when to use rescue medicine).
   Purpose: Reduce injury and get help at the right time.
   Mechanism: Practical steps lower risk and speed care.

2. Individual seizure action plan
   Description: A one-page plan with triggers, medicines, and when to call emergency services.
   Purpose: Consistent, quick response at home and school.
   Mechanism: Clear instructions prevent delays and errors.

3. Dietary therapy: ketogenic or modified ketogenic diet
   Description: High-fat, very low-carb medical diets supervised by a specialist team.
   Purpose: Reduce seizure frequency when drugs are not enough.
   Mechanism: Ketones change brain energy use and lower excitability. Evidence shows better odds of ≥50% seizure reduction versus starting another drug in children with drug-resistant epilepsy. The Lancet+1

4. Speech and language therapy (with AAC when needed)
   Description: Early, frequent therapy; use picture boards, tablets, or speech devices if speech is limited.
   Purpose: Improve understanding and expression.
   Mechanism: Repetition and alternative channels build communication pathways.

5. Physical therapy for spasticity and mobility
   Description: Stretching, positioning, strengthening, gait training, and orthoses.
   Purpose: Maintain range of motion, reduce falls, delay contractures.
   Mechanism: Regular movement reduces increased muscle tone (measured by tools like the Modified Ashworth Scale). NCBI

6. Occupational therapy and activities of daily living (ADL) training
   Description: Practice dressing, feeding, and self-care; adapt the environment and tools.
   Purpose: Maximize independence and caregiver relief.
   Mechanism: Task-specific practice rewires motor planning.

7. Feeding and swallowing therapy
   Description: Assessment of chewing, swallowing safety, and nutrition planning.
   Purpose: Prevent aspiration and improve growth.
   Mechanism: Safer textures and strategies reduce choking risk.

8. Dental rehabilitation under specialist pediatric dentistry
   Description: Fluoride varnish, stainless steel crowns, composite restorations; sometimes treatment under general anesthesia when cooperation is not possible.
   Purpose: Protect weak enamel, reduce pain and sensitivity, restore function and appearance.
   Mechanism: Strong coverings prevent wear/decay and improve quality of life. Turkish Archives of Pediatrics

9. Regular oral-hygiene coaching
   Description: Daily high-fluoride toothpaste, soft brushes, caregiver brushing, and 3–4-monthly hygiene visits.
   Purpose: Lower caries risk in fragile enamel.
   Mechanism: Fluoride strengthens enamel; plaque control prevents decay. PMC

10. Behavioral support and structured routines
    Description: Applied behavior strategies, visual schedules, calm sensory environments.
    Purpose: Reduce distress and improve participation.
    Mechanism: Predictable routines lower arousal and triggers.

11. Sleep hygiene program
    Description: Regular schedule, dark quiet room, no screens before bed; evaluate for nocturnal seizures.
    Purpose: Better sleep helps learning and may reduce seizures.
    Mechanism: Sleep stabilizes brain networks.

12. Assistive seating and mobility devices
    Description: Wheelchairs, walkers, standing frames, supportive seating.
    Purpose: Safer posture and participation.
    Mechanism: Proper alignment reduces spasticity-related strain.

13. Orthoses and serial casting
    Description: Ankle-foot orthoses, hand splints, and short casting programs.
    Purpose: Maintain joint position, delay contractures.
    Mechanism: Constant gentle stretch counters tight muscles.

14. Vision and hearing assessments with aids
    Description: Regular screening and correction.
    Purpose: Support communication and therapy progress.
    Mechanism: Clear sensory input boosts learning.

15. School-based special education and therapy integration
    Description: Individualized education plan (IEP), on-site PT/OT/SLT.
    Purpose: Access to learning at the child’s level.
    Mechanism: Repetition and supports in natural settings.

16. Social work and care coordination
    Description: Help with equipment, transport, respite, and financial resources.
    Purpose: Reduce caregiver burden and missed care.
    Mechanism: Practical supports keep therapy consistent.

17. Genetic counseling for the family
    Description: Explain inheritance, carrier testing, and reproductive options.
    Purpose: Informed future planning.
    Mechanism: Targeted testing and counseling reduce uncertainty. Turkish Archives of Pediatrics

18. Bone health program
    Description: Weight-bearing, vitamin D/calcium intake, fall-prevention.
    Purpose: Limit fracture risk with limited mobility.
    Mechanism: Stronger bones and safer movement.

19. Community emergency plan
    Description: Train school, daycare, and relatives on rescue steps and device magnets (for VNS users).
    Purpose: Faster response outside home.
    Mechanism: Shared knowledge shortens time to treatment. American Academy of Neurology

20. Palliative and supportive care when appropriate
    Description: Symptom control, goals-of-care talks, and respite.
    Purpose: Comfort, dignity, and family support across the course.
    Mechanism: Team approach manages complex needs.

---

Drug treatments

⚠️ Important safety note: Doses below are typical clinical ranges from reputable labels/guidelines. Exact dose, combinations, and monitoring must be individualized by a specialist, especially in infants and children.

1. Levetiracetam (antiepileptic)
   Dose: Children typically titrated up to about 60 mg/kg/day in 2 doses; older/larger patients up to 3000 mg/day. Start low and increase every ~2 weeks.
   Timing: Twice daily.
   Purpose: Broad-spectrum seizure control.
   Mechanism: SV2A modulation stabilizes neurotransmitter release.
   Side effects: Irritability, somnolence; rare mood changes. DailyMed+1

2. Valproate / Valproic acid (antiepileptic)
   Dose: Start 10–15 mg/kg/day, increase weekly by 5–10 mg/kg/day; max 60 mg/kg/day.
   Timing: Divided doses.
   Purpose: Generalized/mixed seizures.
   Mechanism: Increases GABA and modulates sodium/calcium channels.
   Side effects: Weight gain, tremor, liver/pancreas toxicity, teratogenicity; monitor labs. FDA Access Data+1

3. Topiramate (antiepileptic)
   Dose: Young children often titrated from 1–3 mg/kg/day toward 5–9 mg/kg/day in 2 doses; older children/adults follow stepwise schedules to 200–400 mg/day as tolerated.
   Purpose: Adjunct or mono-therapy for generalized and focal seizures.
   Mechanism: Sodium channel block, GABA enhancement, carbonic anhydrase inhibition.
   Side effects: Tingling, appetite loss, kidney stones, word-finding issues. FDA Access Data+1

4. Clobazam (benzodiazepine for epilepsy, including LGS)
   Dose: Weight-based; often 5–20 mg/day divided; adjust in CYP2C19 poor metabolizers.
   Purpose: Reduce drop attacks and other seizures.
   Mechanism: GABA-A receptor positive modulation.
   Side effects: Sedation, drooling, behavioral changes; tolerance can develop. FDA Access Data+2FDA Access Data+2

5. Lamotrigine (antiepileptic; dosing depends on valproate co-use)
   Dose: Complex weight-based schedules; typical maintenance ranges 4.5–15 mg/kg/day in 2 doses (lower with valproate, higher without).
   Purpose: Focal/generalized seizures; mood benefits.
   Mechanism: Sodium channel block; glutamate modulation.
   Side effects: Rash (rare SJS), dizziness; careful slow titration. Drugs.com+1

6. Oxcarbazepine (antiepileptic)
   Dose: Start 8–10 mg/kg/day (twice daily); may increase over 2–4 weeks; max about 60 mg/kg/day (or 30 mg/kg twice daily).
   Purpose: Focal-onset seizures.
   Mechanism: Sodium channel modulation.
   Side effects: Low sodium, dizziness, rash. FDA Access Data+1

7. Perampanel (antiepileptic; adjunct)
   Dose: Typically start 2 mg nightly; slow titration to effectiveness/tolerability.
   Purpose: Add-on for focal/generalized seizures; a published KTS case reported benefit.
   Mechanism: Non-competitive AMPA receptor antagonist.
   Side effects: Dizziness, irritability, behavioral changes; falls. BioMed Central

8. Cannabidiol (Epidiolex®; antiseizure)
   Dose: Start 2.5 mg/kg twice daily, titrate; usual maintenance 10–20 mg/kg/day; some data up to 25 mg/kg/day (TSC).
   Purpose: Add-on in developmental and epileptic encephalopathies.
   Mechanism: Multiple targets; reduces excitability and inflammation.
   Side effects: Sleepiness, diarrhea, ↑LFTs; check for drug–drug interactions. PMC

9. Clonazepam (benzodiazepine)
   Dose: Individualized, small divided doses; slow titration.
   Purpose: Myoclonic and generalized seizures.
   Mechanism: GABA-A modulation.
   Side effects: Sedation, drooling, tolerance.

10. Phenobarbital (barbiturate)
    Dose: Weight-based; used more in infants/low-resource settings.
    Purpose: Broad antiseizure effect when others fail.
    Mechanism: GABA-A potentiation.
    Side effects: Sedation, behavior/cognition impact.

11. Vigabatrin
    Dose: Weight-based titration.
    Purpose: Infantile spasms and focal seizures in specific contexts.
    Mechanism: Irreversible GABA-transaminase inhibitor (↑GABA).
    Side effects: Visual field loss risk; ophthalmology monitoring.

12. Zonisamide
    Dose: Weight-based; once-daily in older children/adults.
    Purpose: Adjunct for focal or generalized seizures.
    Mechanism: Sodium and T-type calcium channel effects; carbonic anhydrase inhibition.
    Side effects: Appetite loss, kidney stones, metabolic acidosis.

13. Lacosamide
    Dose: Weight-based; divided twice daily.
    Purpose: Adjunct for focal seizures.
    Mechanism: Enhances slow inactivation of sodium channels.
    Side effects: Dizziness, PR-interval prolongation.

14. Rufinamide
    Dose: Weight-based, divided doses with food.
    Purpose: Particularly for Lennox-Gastaut–type drop attacks.
    Mechanism: Sodium channel modulation.
    Side effects: Nausea, somnolence; QT shortening.

15. Diazepam (rescue)—nasal spray (Valtoco®)
    Dose: Age/weight-based fixed devices (5–20 mg). Second dose ≥4 hours later if needed; do not exceed label limits (no more than 2 doses per cluster, and monthly limits apply).
    Purpose: Stop seizure clusters outside the hospital.
    Mechanism: Rapid GABA-A activation.
    Side effects: Sleepiness, breathing suppression risk if repeated or mixed with other sedatives. VALTOCO® (diazepam nasal spray)+1

16. Midazolam (rescue)—nasal spray (Nayzilam®)
    Dose: Fixed 5 mg device (often ≥12 years per label); a second 5 mg can be given after 10 minutes in the other nostril; observe labeled limits.
    Purpose: Rapid treatment of clusters/ongoing seizures.
    Mechanism: Fast GABA-A activation.
    Side effects: Sedation; breathing suppression if overused. FDA Access Data

17. Baclofen (oral) for spasticity
    Dose: Start low (e.g., 5 mg three times daily in older/larger patients; weight-based in children); titrate to effect.
    Purpose: Reduce muscle stiffness to ease care and comfort.
    Mechanism: GABA-B agonist reduces spinal reflexes.
    Side effects: Sleepiness, weakness; avoid abrupt stop. NCBI

18. Tizanidine (oral) for spasticity
    Dose: Slow titration.
    Purpose: Alternative or add-on for tone.
    Mechanism: Alpha-2 agonist lowers motor neuron activity.
    Side effects: Sedation, low blood pressure, liver enzyme rise.

19. Botulinum toxin type A (focal spasticity)
    Dose: Per-muscle units by specialist.
    Purpose: Targeted relief in tight muscle groups.
    Mechanism: Blocks acetylcholine at neuromuscular junction.
    Side effects: Local weakness, pain at injection.

20. Melatonin (sleep support)
    Dose: Bedtime dosing (age-appropriate).
    Purpose: Improve sleep routines that support daytime learning and seizure control.
    Mechanism: Aligns sleep–wake cycles.
    Side effects: Morning sleepiness, vivid dreams.

---

Dietary molecular supplements

⚠️ Always review supplements with the treating team, especially if using a ketogenic diet or if the child takes antiseizure medicines.

1. Vitamin D (per labs/age needs)
   Function: Bone strength, muscle function.
   Mechanism: Improves calcium handling; important with limited mobility.

2. Calcium (diet or supplement as needed)
   Function: Bone mineral support.
   Mechanism: Builds and maintains bone along with vitamin D.

3. Selenium
   Function: Required in many ketogenic-diet programs to prevent deficiency.
   Mechanism: Antioxidant selenoproteins; deficiency can cause cardiomyopathy; teams often supplement during ketogenic therapy. Wiley Online Library

4. Multivitamin/mineral (sugar-free)
   Function: General micronutrient cover, especially on ketogenic diets.
   Mechanism: Prevents gaps due to restricted foods. Wiley Online Library

5. Carnitine (if deficient or on valproate, per labs)
   Function: Fat metabolism support; sometimes used in valproate-treated patients.
   Mechanism: Aids transport of fatty acids into mitochondria.

6. Omega-3 fatty acids
   Function: Anti-inflammatory support; may help mood and attention.
   Mechanism: Changes cell-membrane mediators.

7. Magnesium (if low)
   Function: Nerve and muscle function.
   Mechanism: Stabilizes NMDA receptors and ion balance.

8. Probiotics (carefully chosen)
   Function: GI comfort on special diets.
   Mechanism: Microbiome support for digestion.

9. High-fluoride toothpaste/varnish (topical)
   Function: Protects weak enamel; reduces sensitivity.
   Mechanism: Remineralizes tooth surfaces and resists acid attack. PMC

10. Protein-dense oral nutrition (as tolerated)
    Function: Growth and muscle maintenance.
    Mechanism: Provides amino acids during high-fat or low-appetite periods.

Immunity-booster / regenerative / stem-cell drugs

There are no approved immune-boosting or stem-cell medicines specific to KTS. Here is what is reasonable and what is under study:

1. Routine vaccines (per schedule)
   Dose: As per national immunization schedule.
   Function/Mechanism: Prevent infections that can trigger seizures or hospital stays.
   Note: Strongly recommended in neurologic disorders.

2. Gene therapy under investigation for SLC13A5 deficiency (TSHA-105)
   Dose: Not established for clinical care; research only.
   Function/Mechanism: AAV9 vector aiming to replace the non-working citrate transporter gene; early regulatory designations granted.
   Safety: Experimental; available only in trials. Taysha Gene Therapies+1

3. Nutritional neuro-support (vitamin D, selenium, carnitine) as above
   Dose: Per labs and diet team.
   Function/Mechanism: Correct deficiencies that can worsen health.

4. Intrathecal baclofen pump (device + drug) for severe spasticity
   Dose: Continuous micro-doses directly into spinal fluid (typical maintenance tens to hundreds of micrograms/day).
   Function/Mechanism: GABA-B agonism reduces severe tone and pain; can be “regenerative-supportive” by enabling therapy and hygiene.
   Note: Surgery and close follow-up required. FDA Access Data+1

5. Clinical-trial metabolic fuels (e.g., triheptanoin) in other encephalopathies
   Dose: Research protocols only; not standard for KTS.
   Function/Mechanism: Anaplerotic energy support; mixed evidence in epilepsy overall.
   Note: Discuss research options with specialists. PMC

6. iPSC-based disease modeling (research tool)
   Dose: Not a therapy.
   Function/Mechanism: Helps scientists test regenerative ideas for future treatments.
   Note: Not available as treatment yet.

---

Surgeries

1. Full-mouth dental rehabilitation (often under general anesthesia)
   Why: Protect weak enamel, stop pain, restore function/appearance when office care is not possible.
   What happens: Crowns, restorations, extractions if needed, fluoride treatment. Turkish Archives of Pediatrics

2. Vagus nerve stimulator (VNS) implantation
   Why: For drug-resistant epilepsy to reduce seizure frequency and severity.
   What happens: A small pulse generator is placed under the skin with a lead to the vagus nerve; later programmed in clinic. American Academy of Neurology

3. Intrathecal baclofen pump placement
   Why: Severe spasticity not controlled by oral medicine.
   What happens: A catheter delivers baclofen into spinal fluid from a small implanted pump; doses are adjusted over time. FDA Access Data

4. Gastrostomy tube (G-tube)
   Why: Unsafe swallowing or poor growth.
   What happens: A feeding tube through the abdomen ensures safe nutrition and medicine delivery.

5. Orthopedic soft-tissue procedures (e.g., tendon lengthening)
   Why: Painful contractures or hip subluxation due to chronic spasticity.
   What happens: Releases tight structures to improve comfort, hygiene, and seating.

---

Preventions

1. Prevent injury during seizures with caregiver training and safe home layout.

2. Vaccinations on schedule to avoid infection-triggered setbacks.

3. Trigger management (illness, sleep loss, flashing lights for some) to lower seizure risk.

4. Dental prevention: fluoride, regular cleanings, and early crowns to protect fragile enamel. PMC

5. Consistent medicines and follow-up to avoid missed doses and withdrawal seizures.

6. Nutrition and hydration to keep energy steady and constipation low.

7. Bone-health steps (weight-bearing, vit D/calcium) to reduce fracture risk.

8. Respiratory hygiene (treat reflux, manage drooling) to prevent aspiration.

9. Safe mobility and orthoses to prevent falls and contractures.

10. Genetic counseling for family planning and early testing in future pregnancies. Turkish Archives of Pediatrics

---

When to see a doctor urgently

• A first seizure, a seizure lasting >5 minutes, repeated seizures without recovery, or breathing problems

• New weakness, severe headache, or sudden behavior change

• Signs of liver trouble on valproate or cannabidiol (vomiting, sleepiness, jaundice)

• Worsening swallowing with coughing or weight loss

• Severe dental pain, swelling, or broken teeth despite crowns FDA Access Data+1

---

What to eat and what to avoid

• If on a medical ketogenic diet: follow the exact plan set by the hospital team. Expect routine supplements (multivitamin, selenium, calcium, vitamin D) and frequent check-ins. Do not change the diet without approval. Wiley Online Library

• If not on ketogenic therapy: choose balanced meals with enough protein, fruits/vegetables, and healthy fats. Encourage fluids and fiber to reduce constipation.

• For teeth: use sugar-free snacks, avoid frequent acidic drinks, and brush twice daily with high-fluoride paste. Professional fluoride varnish and early crowns protect enamel and reduce sensitivity. PMC

• Avoid unsupervised supplements that interact with seizure medicines, crash diets, and sweet/chewy foods that cling to enamel.

---

Frequently asked questions (FAQs)

1) Is there a cure?
Not yet. Treatment focuses on seizures, development, comfort, and teeth protection. Research into gene-based therapy exists for SLC13A5 deficiency, but it is still experimental. Taysha Gene Therapies

2) Why are the teeth affected?
Because the genes involved help enamel-making cells. When they fail, enamel can be too thin, too soft, or badly mineralized, leading to yellow, sensitive teeth. Turkish Archives of Pediatrics

3) Can ketogenic diets help seizures?
Yes, for some children with drug-resistant epilepsy; they must be medically supervised, and supplements are usually required. The Lancet+1

4) Do most children need multiple seizure medicines?
Often yes, especially early on. The team carefully adjusts drugs to balance benefits and side effects, and may add rescue nasal medicines for clusters. FDA Access Data

5) What does VNS do?
It gently stimulates the vagus nerve to reduce seizure burden in drug-resistant epilepsy. It is an implant and needs follow-up programming. American Academy of Neurology

6) What does MRI show?
MRI can be normal or show delayed myelination or white-matter changes; findings vary. Turkish Archives of Pediatrics

7) How is the diagnosis confirmed?
By genetic testing for ROGDI or SLC13A5. Dental findings can be an early clue that prompts genetic referral. Turkish Archives of Pediatrics

8) Are there specific medicines proven best for KTS?
No single drug fits all. Levetiracetam, valproate, topiramate, clobazam, lamotrigine, and others are commonly used; one KTS case reported benefit with perampanel. BioMed Central

9) Is cannabidiol (Epidiolex®) an option?
It can be considered in certain epilepsy syndromes; dosing is weight-based and requires liver-test monitoring and interaction checks. PMC

10) Will my child walk or talk?
Outcomes vary widely. Early therapy, seizure control, and support services help each child reach their personal best.

11) Do we need to see a dentist more often?
Yes—because enamel is fragile. Preventive visits every 3–4 months, high-fluoride care, and early crowns are common. Turkish Archives of Pediatrics

12) Can school support be arranged?
Yes—an individualized plan with therapies at school improves participation.

13) What about spasticity?
Tone can be helped by therapy, oral baclofen or tizanidine, focal botulinum toxin, and for severe cases, an intrathecal baclofen pump. NCBI+1

14) How can families plan for future children?
Genetic counseling offers carrier tests and reproductive options. Turkish Archives of Pediatrics

15) Where can we read more?
Ask for reputable sources such as peer-reviewed genetics and epilepsy organizations. The items cited above are a good start.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 14, 2025.